$3.04
3.40% yesterday
Nasdaq, Aug 12, 10:00 pm CET
ISIN
US03528H1095
Symbol
ANIX

Anixa Biosciences, Inc. Stock price

$3.04
-0.16 5.00% 1M
-0.10 3.18% 6M
+0.72 31.03% YTD
-0.15 4.70% 1Y
-1.02 25.12% 3Y
+0.41 15.37% 5Y
-1.18 27.96% 10Y
-9.46 75.68% 20Y
Nasdaq, Closing price Tue, Aug 12 2025
+0.10 3.40%
ISIN
US03528H1095
Symbol
ANIX
Industry

Key metrics

Basic
Market capitalization
$94.7m
Enterprise Value
$79.1m
Net debt
positive
Cash
$15.6m
Shares outstanding
32.2m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
5.9
Financial Health
Equity Ratio
92.6%
Return on Equity
-62.8%
ROCE
-87.1%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-13.1m | -
EBIT
$-13.1m | $-14.2m
Net Income
$-12.1m | $-13.0m
Free Cash Flow
$-8.0m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
- | -
EBIT
-1.4% | -2.9%
Net Income
-4.7% | -3.4%
Free Cash Flow
-11.3%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-0.4
FCF per Share
$-0.2
Short interest
1.2%
Employees
5
Rev per Employee
$0.0
Show more

Is Anixa Biosciences, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

Anixa Biosciences, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Anixa Biosciences, Inc. forecast:

8x Buy
89%
1x Hold
11%

Analyst Opinions

9 Analysts have issued a Anixa Biosciences, Inc. forecast:

Buy
89%
Hold
11%

Financial data from Anixa Biosciences, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Apr '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 6.87 6.87
6% 6%
-
- Research and Development Expense 6.28 6.28
10% 10%
-
-13 -13
-
-
- Depreciation and Amortization 0.06 0.06
-
-
EBIT (Operating Income) EBIT -13 -13
1% 1%
-
Net Profit -12 -12
5% 5%
-

In millions USD.

Don't miss a Thing! We will send you all news about Anixa Biosciences, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Anixa Biosciences, Inc. Stock News

Neutral
PRNewsWire
about 11 hours ago
Newly issued patent extends protection of proprietary solid tumor CAR-T platform to 2045 SAN JOSE, Calif. , Aug. 12, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent Number 12,384,826 c...
Neutral
PRNewsWire
4 days ago
Dr. Wenham is Principal investigator on Anixa's CAR-T therapy for Ovarian Cancer SAN JOSE, Calif. , Aug. 8, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced Dr. Robert Wenham, Chair of the Gynecologic Oncology Program at Moffitt Cancer Center and principal investigat...
Neutral
PRNewsWire
8 days ago
Progress Follows Positive Immune Response Observed in Phase 1 Study SAN JOSE, Calif. , Aug. 4, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that, in collaboration with Cleveland Clinic, it has initiated the transfer of the Investigational New Drug (IND) applicati...
More Anixa Biosciences, Inc. News

Company Profile

Anixa Biosciences, Inc. is a cancer-focused biotechnology company, which focuses on harnessing the body's immune system in the fight against cancer. It operates through the following segments: Cancer Diagnostics, Cancer Therapeutics, and Legacy Patent Licensing Activities. Cancer Diagnostic segment develops CchekTM platform, a series of inexpensive non-invasive blood tests for the early detection of solid tumors, which is based on the body's immune response to the presence of a malignancy. Cancer Therapeutics segment offers chimeric antigen receptor T-cell (CAR-T) based immuno-therapy drugs which genetically engineer a patient's own immune cells to fight cancer. The company was founded on November 5, 1982 and is headquartered San Jose, CA.

Head office United States
CEO Amit Kumar
Employees 5
Founded 1982
Website www.anixa.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today